With the now global outbreak of the novel SARS-like coronavirus, SARS-CoV-2 (2019-nCoV, COVID-19 virus), access to research tools has become critical to better understand the pathophysiology of the disease and develop specific and efficient novel therapeutics and prevention methods. Scientists identified the novel coronavirus as a group 2B CoV, distinct from the SARS-CoV. Genome sequencing indicated that SARS-CoV-2 (2019-nCoV) shares 79.5% sequence identity with SARS-CoV. It is therefore essential to assess SARS-CoV-2 specificity of research reagents. RayBiotech, distributed by tebu-bio in Europe, has made very special efforts to allow fast release of SARS-CoV-2 validated tools. This post introduces this new range of detection reagents, proteins and antibodies now available to boost COVID-19 research in Europe.

The cGAS-cGAMP-STING cell signalling pathway plays a critical role in antiviral and antitumor immunity as well as mediating autoimmune responses. Dysregulation or aberrant activation of the pathway by self-DNA has emerged as an underlying cause of tumorigenesis and autoimmune disorders. As the critical role of cyclic dinucleotides in pathophysiology continues to emerge, new tools to study these signaling pathways are being developed. This post introduces the latest ELISA released on the market.

tebu-bio is pleased to announce their new partnership for a European distribution of Novabiosis, a US based manufacturer providing cryopreserved primary human cells for the biotechnology, pharmaceutical and medical research fields. Their focus is on Kidney, Intestine, Lung and Liver tissues. They have developed multiple cell types for each organ, an asset for co-culture studies or 3D models development.

Now that the novel coronavirus (2019-nCoV or COVID-19) outbreak has been declared a “public health emergency of international concern” by the WHO, scientists worldwide are being pressured to develop a treatment. The first step of research projects focussing on this virus is to identify robust anti-COVID antibodies.

Some antibodies developed for the 2002 SARS strain present opportunities for immediate deployment while others have been recently made available to the research community. In this post, you’ll find a selection of the most sought after anti-COVID research antibodies.